CI

At a glance

ClinicalIndex Comparison Record
Phase 3Recruiting· 42 target
Drug / intervention
Haloperidol +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05431595
NCT05431595Phase 3RecruitingOn TrackUpdated 7mo ago
Long Recruiting

Managing Agitated Delirium With Neuroleptics and Anti-Epileptics as a Neuroleptic Sparing Strategy

M.D. Anderson Cancer Center·interventional·Posted Jun 24, 2022·Updated Nov 18, 2025

In Brief

A Phase 3 clinical trial evaluating Haloperidol, Chlorpromazine, and 2 other interventions for Delirium and 2 related conditions. Currently recruiting, targeting 42 participants across 1 site.

Detailed Summary

To examine the effects of haloperidol, chlorpromazine, valproic acid and placebo, in conjunction with standardized non-pharmacologic interventions, in the first line treatment of agitated delirium in hospitalized patients with cancer. This double-blind, randomized clinical trial aims to provide evidence on various therapeutic options for palliating delirium, thereby reducing delirium-related distress and ultimately alleviating suffering.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States

Timeline

Phase 3Recruiting
20232024202520262027
First PostedJun 24, 2022
Enrollment StartJul 19, 2022
Primary CompletionFeb 2, 2027
TodayJul 1, 2026
Enrollment to primary: 4.5 yearsPosted 4.0 years agoPrimary completion in 7 months

Interventions

Haloperidoldrug

Given by Vein (IV)

Chlorpromazinedrug

Given by Vein (IV)

Valproatedrug

Given by Vein (IV)

Placebodrug

Given by Vein (IV)